CRISTAL: Protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study

BMJ Open

Volumn 9, Issue 11, 2019, Pages

  Sidhu, Verinder Singh ^a   Graves, Steven E ^b   Buchbinder, Rachelle ^c,d   Naylor, Justine Maree ^a   Pratt, Nicole L ^e   De Steiger, Richard S ^f   Chong, Beng H ^a   Ackerman, Ilana N ^c   Adie, Sam ^a   Harris, Anthony ^c   Hansen, Amber ^a   Cripps, Maggie ^a   Lorimer, Michelle ^g   Webb, Steve ^c,h   Clavisi, Ornella ⁱ   Griffith, Elizabeth C ^g   Anandan, Durga ^b   O'Donohue, Grace ^b   Kelly, Thu Lan ^e   Harris, Ian A ^a,j  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b South Australian Health and Medical Research Institute   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d CABRINI INSTITUTE   (Australia)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^h ST JOHN OF GOD HOSPITAL   (Australia)

ⁱ Musculoskeletal Australia   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

aspirin; deep venous thrombosis; hip arthroplasty; knee arthroplasty; low molecular weight heparin; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL OUTCOME; CLINICAL TRIAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; ELECTIVE SURGERY; FOLLOW UP; HEALTH STATUS; HIP OSTEOARTHRITIS; HOSPITAL READMISSION; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTICENTER STUDY; NON-INFERIORITY TRIAL; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; POSTOPERATIVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL; REOPERATION; REVISION ARTHROPLASTY; STUDY DESIGN; THROMBOSIS PREVENTION; TOTAL HIP REPLACEMENT; TOTAL KNEE ARTHROPLASTY; VENOUS THROMBOEMBOLISM; AUSTRALIA; COMPARATIVE STUDY; EQUIVALENCE TRIAL (TOPIC); HIP REPLACEMENT; KNEE REPLACEMENT; POSTOPERATIVE COMPLICATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ASPIRIN; AUSTRALIA; CROSS-OVER STUDIES; EQUIVALENCE TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; VENOUS THROMBOEMBOLISM;

EID: 85074714941     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2019-031657     Document Type: Article

References (40)

1. AOA. Australian Orthopaedic Association national joint replacement registry annual report, 2017.
2. An VVG, Phan K, Levy YD, et al. Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty 2016;31:2608-16.
3. Mirkazemi C, Bereznicki LR, Peterson GM. Comparing Australian orthopaedic surgeons' reported use of thromboprophylaxis following arthroplasty in 2012 and 2017. BMC Musculoskelet Disord 2019;20:57.
4. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTe in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ED: American College of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e27 8S-325.
5. Mont MA, Jacobs JJ, Boggio LN, et al. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg 2011;19:768-76.
6. NICE. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism, 2018.
7. Jenny J-Y, Pabinger I, Samama CM, et al. European guidelines on perioperative venous thromboembolism prophylaxis: aspirin. Eur J Anaesthesiol 2018;35:123-9.
8. Russell RD, Huo MH. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. J Arthroplasty 2013;28:1477-81.
9. Nieto JA, Espada NG, Merino RG, et al. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res 2012;130:183-91.
10. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
11. Turun S, Banghua L, Yuan Y, et al. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb Res 2011;127:525-34.
12. NHMRC. National Health and Medical Research Council. Clinical Practice Guideline for the Prevention of Venous Thromboembolism-Rescinded, 2009.
13. Adam SS, McDuffie JR, Lachiewicz PF, et al. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med 2013;159:275-84.
14. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012;344:e3675.
15. Cao YB, Zhang JD, Shen H, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010;66:1099-108.
16. Cohen A, Drost P, Marchant N, et al. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. Clin Appl Thromb Hemost 2012;18:611-27.
17. Harenberg J, Marx S, Dahl OE, et al. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thromb Haemost 2012;108:903-12.
18. Neumann I, Rada G, Claro JC, et al. Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012;156:710-9.
19. Wilson DGG, Poole WEC, Chauhan SK, et al. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty. Bone Joint J 2016;98-B: 1056-61.
20. Drescher FS, Sirovich BE, Lee A, et al. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med 2014;9:579-85.
21. Anderson DR, Dunbar MJ, Kahn SR. Aspirin versus low-molecular-weight heparin after total hip arthroplasty. Ann Intern Med 2013;159:502-3.
22. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTe prophylaxis after hip or knee arthroplasty. N Engl J Med 2018;378:699-707.
23. Bozic KJ, Vail TP, Pekow PS, et al. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty 2010;25:1053-60.
24. Jameson SS, Baker PN, Charman SC, et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using national joint registry data. J Bone Joint Surg Br 2012;94:914-8.
25. Jameson SS, Charman SC, Gregg PJ, et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National joint registry. J Bone Joint Surg Br 2011;93:1465-70.
26. Molnar RB, Jenkin DE, Millar MJ, et al. The Australian arthroplasty thromboprophylaxis survey. J Arthroplasty 2012;27:173-9.
27. Murray DW, Fitzpatrick R, Rogers K, et al. The use of the Oxford hip and knee scores. J Bone Joint Surg Br 2007;89:1010-4.
28. EuroQol Group. EuroQol-A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
29. Muñoz-Venturelli P, Arima H, Lavados P, et al. Head Position in Stroke Trial (HeadPoST)-sitting-up vs lying-flat positioning of patients with acute stroke: study protocol for a cluster randomised controlled trial. Trials 2015;16:256.
30. van Duijn PJ, Verbrugghe W, Jorens PG, et al. The effects of antibiotic cycling and mixing on antibiotic resistance in intensive care units: a cluster-randomised crossover trial. Lancet Infect Dis 2018;18:401-9.
31. Rolfson O, Bohm E, Franklin P, et al. Patient-Reported outcome measures in arthroplasty registries report of the patient-reported outcome measures Working group of the International Society of arthroplasty registries Part II. recommendations for selection, administration, and analysis. Acta Orthop 2016;87:9-23.
32. Wang CJ, Wang JW, Weng LH, et al. Outcome of calf deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg Br 2003;85:841-4.
33. Kulshrestha V, Kumar S. DVT prophylaxis after TKA: routine anticoagulation vs risk screening approach-A randomized study. J Arthroplasty 2013;28:1868-73.
34. Bawa H, Weick JW, Dirschl DR, et al. Trends in deep vein thrombosis prophylaxis and deep vein thrombosis rates after total hip and knee arthroplasty. J Am Acad Orthop Surg 2018;26:698-705.
35. Giraudeau B, Ravaud P, Donner A. Sample size calculation for cluster randomized cross-over trials. Stat Med 2008;27:5578-85.
36. Kelly T-L, Pratt N. A note on sample size calculations for cluster randomised crossover trials with a fixed number of clusters. Stat Med 2019;38:3342-5.
37. Cimminiello C, Prandoni P, Agnelli G, et al. Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg Med 2017;12:1291-305.
38. Turner RM, White IR, Croudace T, et al. Analysis of cluster randomized cross-over trial data: a comparison of methods. Stat Med 2007;26:274-89.
39. Forbes AB, Akram M, Pilcher D, et al. Cluster randomised crossover trials with binary data and unbalanced cluster sizes: application to studies of near-universal interventions in intensive care. Clin Trials 2015;12:34-44.
40. White IR, Daniel R, Royston P. Avoiding bias due to perfect prediction in multiple imputation of incomplete categorical variables. Comput Stat Data Anal 2010;54:2267-75.